Skip to main content

CAP--advancing the evaluation of preclinical Alzheimer disease treatments.

Publication ,  Journal Article
Reiman, EM; Langbaum, JB; Tariot, PN; Lopera, F; Bateman, RJ; Morris, JC; Sperling, RA; Aisen, PS; Roses, AD; Welsh-Bohmer, KA; Carrillo, MC ...
Published in: Nat Rev Neurol
January 2016

If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the initiation and performance of preclinical AD trials. In this article, we note some of the current challenges, opportunities and emerging strategies in preclinical AD treatment. We describe the Collaboration for Alzheimer's Prevention (CAP)-a convening, harmonizing and consensus-building initiative to help stakeholders advance AD prevention research with rigour, care and maximal impact-and we demonstrate the impact of CAP on the goals and design of new preclinical AD trials.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Rev Neurol

DOI

EISSN

1759-4766

Publication Date

January 2016

Volume

12

Issue

1

Start / End Page

56 / 61

Location

England

Related Subject Headings

  • Treatment Outcome
  • Randomized Controlled Trials as Topic
  • Prodromal Symptoms
  • Nootropic Agents
  • Neuropsychological Tests
  • Neurology & Neurosurgery
  • Interdisciplinary Communication
  • Humans
  • Guideline Adherence
  • Early Diagnosis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reiman, E. M., Langbaum, J. B., Tariot, P. N., Lopera, F., Bateman, R. J., Morris, J. C., … Weninger, S. (2016). CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol, 12(1), 56–61. https://doi.org/10.1038/nrneurol.2015.177
Reiman, Eric M., Jessica B. Langbaum, Pierre N. Tariot, Francisco Lopera, Randall J. Bateman, John C. Morris, Reisa A. Sperling, et al. “CAP--advancing the evaluation of preclinical Alzheimer disease treatments.Nat Rev Neurol 12, no. 1 (January 2016): 56–61. https://doi.org/10.1038/nrneurol.2015.177.
Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, et al. CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol. 2016 Jan;12(1):56–61.
Reiman, Eric M., et al. “CAP--advancing the evaluation of preclinical Alzheimer disease treatments.Nat Rev Neurol, vol. 12, no. 1, Jan. 2016, pp. 56–61. Pubmed, doi:10.1038/nrneurol.2015.177.
Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, Sperling RA, Aisen PS, Roses AD, Welsh-Bohmer KA, Carrillo MC, Weninger S. CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol. 2016 Jan;12(1):56–61.

Published In

Nat Rev Neurol

DOI

EISSN

1759-4766

Publication Date

January 2016

Volume

12

Issue

1

Start / End Page

56 / 61

Location

England

Related Subject Headings

  • Treatment Outcome
  • Randomized Controlled Trials as Topic
  • Prodromal Symptoms
  • Nootropic Agents
  • Neuropsychological Tests
  • Neurology & Neurosurgery
  • Interdisciplinary Communication
  • Humans
  • Guideline Adherence
  • Early Diagnosis